Asset Purchase Agreement Between Faulding Pharmaceutical Co. and NaPro BioTherapeutics, Inc. August 25, 2003Iii Asset Purchase Agreement • August 28th, 2003 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Delaware
This Asset Purchase Agreement (this "Agreement") is entered into on August 25, 2003, between Faulding Pharmaceutical Co., a Delaware corporation ("Buyer"), and NaPro BioTherapeutics, Inc., a Delaware corporation ("Seller"). Buyer and Seller are each referred to in this Agreement as a "Party" and collectively as the "Parties."
VOTING AGREEMENTVoting Agreement • August 28th, 2003 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Delaware
Concurrently with the execution of this Agreement, Buyer and the Company have entered into an Asset Purchase Agreement dated as of August 25, 2003 (the "Purchase Agreement") pursuant to which Buyer will acquire the Paclitaxel Business of the Company (the "Asset Purchase"). The transactions contemplated by the Purchase Agreement are collectively referred to as the "Transactions." Capitalized terms not defined in this Agreement have the meanings given them in the Purchase Agreement.
